Biologics‐Loaded Photothermally Dissolvable Hyaluronic Acid Microneedle Patch for Psoriasis Treatment

Abstract

Emerging biologics, such as monoclonal antibodies (mAbs), are the most promising treatment for psoriasis, while their effective delivery to the local inflammatory area of the skin is a challenge. Here, a novel photo‐thermally dissolvable hyaluronic acid microneedle patch is presented with biologics IL‐17 mAbs and MXene encapsulation for psoriasis treatment. As the microneedles possess suitable mechanical strength and great biocompatibility, they can puncture the skin with minimal immune response. In addition, owing to the advantages of superior photothermal conversion efficiency of MXene additive, the microneedle patch can rapidly melt and release the encapsulated IL‐17 mAbs into the dermis under near‐infrared light irradiation for effective anti‐inflammatory effect around the psoriasis lesions. Based on these features, the multifunctional microneedle patch can effectively reduce psoriasis‐like skin inflammation in an imiquimod‐induced animal model, resulting in a desired therapeutic effect. Thus, the proposed microneedle delivery system provides a safer and effective strategy for psoriasis treatment, which is also valuable to improve the clinical efficacy of biologics‐based treatment for other chronic inflammatory autoimmune diseases.

Reactive Oxygen Species-Responsive Gel-Based Microneedle Patches for Prolonged and Intelligent Psoriasis Management

“…Though MNs did not cover the whole ear, the released drugs can diffuse in the skins and transport to lymph nodes, thus inhibiting the progression of psoriasis in an area larger than patch size (Figure S21). 65,66 The mice in the MTX-HA group also had thinner ear and epidermal thicknesses than those of the untreated groups, indicating the released MTX had therapeutic effect for psoriasis. However, the treatment in MTX-HA and MTX/ EGCG-HA was less efficient than in the EGCG-HP and MTX/ EGCG-HP groups demonstrating the advantages of sustained and intelligent release of EGCG in psoriasis management.…”

Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy

“…Light is a frequently used exogenous stimulus in the clinical application of various diseases [102][103][104][105]. Due to the advantages of spatiotemporal selectivity, remote controllability, noninvasiveness, and convenient operation, lightresponsive DDSs based on phototherapies including photoactivated chemotherapy [106,107], photodynamic therapy (PDT) [108][109][110][111], photothermal therapy (PTT) [112][113][114], etc., have been broadly used for cancer treatment [115,116]. By using the light-controllable DDSs, on-demand drug/ gene/protein release could be achieved for precision strikes against cancer cells.…”

Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis

“…Transdermal drug delivery is an effective route for the treatment of skin diseases, because it allows direct targeting of lesions on the skin and reduces the side effects associated with systemic drug delivery (90)(91)(92)(93). However, the skin barrierstratum corneum could greatly impair the bioavailability of transdermal drug delivery.…”

“…unique advantages, microneedles have been widely used as effective transdermal drug delivery tools for the treatment of skin diseases including psoriasis (90,91,94). Du et al developed a microneedle patch made with hyaluronic acid (HA) and encapsulated MTX into the patch, which could effectively penetrate the IMQ-induced mouse epidermis and impair psoriasis-like skin inflammation in mice (95).…”

“…Microneedles is a type of new drug delivery systems developed in recent years, which can significantly improve the permeability and increase the bioavailability of therapeutic agents by piercing the stratum corneum and creating a large number of reversible microchannels in a minimally invasive manner. Due to these unique advantages, microneedles have been widely used as effective transdermal drug delivery tools for the treatment of skin diseases including psoriasis ( 90 , 91 , 94 ). Du et al.…”